KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF): 2010-2024

Historic Depreciation & Amortization (CF) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $80.4 million.

  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) rose 23.40% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.4 million, marking a year-over-year increase of 2.58%. This contributed to the annual value of $80.4 million for FY2024, which is 5.24% down from last year.
  • As of FY2024, Supernus Pharmaceuticals' Depreciation & Amortization (CF) stood at $80.4 million, which was down 5.24% from $84.9 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $85.5 million for FY2022, and its period low was $18.1 million during FY2020.
  • Over the past 3 years, Supernus Pharmaceuticals' median Depreciation & Amortization (CF) value was $84.9 million (recorded in 2023), while the average stood at $83.6 million.
  • In the last 5 years, Supernus Pharmaceuticals' Depreciation & Amortization (CF) soared by 172.43% in 2020 and then dropped by 5.24% in 2024.
  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) (MRY) stood at $18.1 million in 2020, then surged by 79.68% to $32.6 million in 2021, then skyrocketed by 162.44% to $85.5 million in 2022, then dropped by 0.80% to $84.9 million in 2023, then decreased by 5.24% to $80.4 million in 2024.
  • Its Depreciation & Amortization (CF) was $80.4 million in FY2024, compared to $84.9 million in FY2023 and $85.5 million in FY2022.